Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03096509
Other study ID # PHT/2016/84
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 19, 2017
Est. completion date March 31, 2018

Study information

Verified date April 2023
Source Portsmouth Hospitals NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Innovations aimed at improving new patient identification, diagnosis, nonpharmacological treatment, supported self-management, and remote monitoring, together with new methods of clinical support could improve outcomes in patients with respiratory disease. The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs. The investigators will assess whether the implementation of the service is effective, and how it can be adjusted, in addition to introducing innovations to assess whether the expected benefits for patients are realised.


Description:

A combination of study designs are required to evaluate all aspects of the service: - Participatory action research approach, involving real-time evaluation at each clinic to inform subsequent clinics - Before-and-after study for patient outcomes pre-clinic attendance and post-clinic attendance. - Qualitative methods (interviews, focus groups) Evaluation of the clinic cycles will include consideration of qualitative data from patients, carers and healthcare professionals, in addition to quantitative outcomes for service implementation and patient factors (i.e. uptake of the service and benefits realised in-session), including those in the following areas: - Clinic process - Education and supported self-management - Added value of diagnostic tools (new diagnoses) - Applicability and use of treatment tools and treatment tailoring - Self-monitoring appropriateness and uptake - Balance measures (e.g. increased secondary care traffic) The longer-term impact of the service will be evaluated using clinical and health service outcomes such as: - Hospitalisations for airways disease - perceived disease control (symptom scores etc) - exacerbation frequency - health-related quality of life - Patient Activation Measures (PAM) - Treatments used - Healthcare resource use (primary and secondary care)


Recruitment information / eligibility

Status Completed
Enrollment 342
Est. completion date March 31, 2018
Est. primary completion date March 31, 2018
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Attendance at a MISSION ABC clinic or training session as a patient, carer or Healthcare Professional Exclusion Criteria: - Unable to give informed consent - Level of literacy precludes inclusion in questionnaire-based study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MISSION ABC Integrated Care clinic
The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.

Locations

Country Name City State
United Kingdom Portsmouth Hospitals NHS Trust Portsmouth

Sponsors (5)

Lead Sponsor Collaborator
Portsmouth Hospitals NHS Trust East Hampshire Better Local Care Fund, Pfizer, The Health Foundation, Wessex Academic Health Science Network

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of clinic process measured through the collection of qualitative feedback. Qualitative feedback forms collected at ever clinical encounter, qualitative interviews at 3 months post clinic and HCP focus groups will generate qualitative data. This will be evaluated cyclically to inform changes in the clinic structure. up to 18 months
Secondary Number of changes in primary diagnosis or classification of disease severity resulting from a MISSION clinic appointment. The number of new or changed diagnoses made as a result of a MISSION clinical encounter will be recorded. 18 months
Secondary Number of additional co-morbid medical conditions identified from a MISSION clinical encounter. The number of co-morbid medical conditions identified by the medical team at a MISSION clinic will be recorded 18 months
Secondary Frequency of uptake and attendance at the enhanced asthma education programme ESMENA The number of patients invited to attend ESMENA who accept the invitation will be recorded. Attendance rates over each 3 sessions will be recorded. 18 months
Secondary Changes in patients' perceived confidence in self-management before and after MISSION clinics and education sessions measured through questionnaire feedback Patients will be asked to fill out a baseline questionnaire exploring their confidence in managing their disease and their health behaviours. They will be asked to rate confidence using a Liekrt scale that will be repeated at 3 and 6 months following their clinical or educational encounters. 18 months
Secondary Uptake and acceptability of HCP education through the MISSION process The numbers and grade of HCP who attend MISSION clinics and dedicated education sessions will be recorded. 10% attendees will be asked to participate in focus group interviews which will explore their beliefs around the value and acceptability of these educational opportunities. 18 months
Secondary Number of patients where inhaler technique is improved at the first MISSION clinical encounter Each patient will undergo an assessment of inhaler technique at their first appointment. Where education is required, it will be recorded if that intervention results in improvement. 18 months
Secondary Number of referrals to the smoking cessation service embedded in the MISSION clinics that results in a quit attempt Data will be extracted from the GP record to indicate if a quit attempt is made 18 months
Secondary Any change in medication recorded The number of new, changed or stopped prescriptions will be recorded. 18 months
Secondary Number of triggers on remote monitoring that can be managed remotely The number of patients using the Message Dynamics or Clinitouch remote monitoring systems who trigger a positive response on symptoms or observations where they can be managed via a supported call rather than a GP attendance will be recorded. Any suspected delay in reporting disease deterioration due to the presence of the remote monitoring systems will also be recorded. 18 months
Secondary Number of additional secondary care referrals made as a result of the MISSION ABC process. As a balancing measure, any secondary care referrals made will be recorded and additional costs to the healthcare system calculated. 18 months
Secondary Change in disease-specific symptom control questionnaires from baseline to 3 and 6 months CAT or ACQ will be measured at baseline and then 3 and 6 months to assess changes in symptom control 6 months
Secondary Change in the productivity measure WPA from baseline to 3 and 6 months Each patient will be asked to fill in the WPA at baseline, 3 and 6 months and the answers compared 6 months
Secondary Change in the patient activation measure from baseline to 3 and 6 months. Each patient will be asked to fill in the PAM at baseline, 3 and 6 months and the answers compared 6 months
Secondary Changes in unscheduled health care usage per patient in the 12 months before and after MISSION ABC For each patient the investigators will record their number of exacerbations, unscheduled GP visits, out-of-hours service calls, ED attendances and admissions in the 12 months before and 12 months after the MISSION clinic. 24 months
Secondary Acceptability of each innovation measured MISSION ABC incorporates several innovative diagnosis and treatment solutions: Thorasys oscillometry, Flo-Tone devices, Airsonett laminar airflow, my mHealth online education, Message Dynamics Remote Monitoring, Clinitouch remote monitoring. For each device patients will be asked to give qualitative feedback. 18 months
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device